China's Innovent prices HK IPO near top end, raises $421 million, say sources: Reuters

Innovent Biologics Inc has priced its Hong Kong initial public offering (IPO) near the top of its marketing range to raise $421 million, sources told Reuters, indicating renewed enthusiasm in a sector blighted by falling stocks.